Close the acquisition of Caelyx and Doxil rights
Delivered by the deadline
Under re-examination This entry has been challenged and is being re-checked against the sources.
- Announced
- 29 Apr 2021
- Due
- 30 Jun 2021
- Delivered
- February 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“We expect the transaction to close late in the first quarter or early in the second quarter of 2021, subject to the satisfaction of regulatory approvals and other closing conditions.”
What we found
Evidence strength A What the grades mean
Baxter International successfully acquired the rights to Caelyx and Doxil for specified territories outside of the U.S. in February 2021, which falls within the stated timeframe.
-
A Baxter International 10-Q filed 2021-10-28
“In February 2021, we acquired the rights to Caelyx and Doxil, the branded versions of liposomal doxorubicin, from a subsidiary of Johnson & Johnson for specified territories outside of the U.S.” ✓ confirmed on the page
Checked 8 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Acquisition close
- Indicative materiality
- High rules
- Action
- Close
- Deliverable
- acquisition of Caelyx and Doxil rights
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: subject to the satisfaction of regulatory approvals and other closing conditions
- Depends on
- Regulatory, Counterparty
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Baxter International? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-BAX-005258 · Corrections policy